IDEXX Laboratories, Inc.
IDXXNASDAQHealthcareDiagnostics & Research
As of Oct 26, 2026 close
- Market cap
- $45.22B
- P/E (TTM)
- 39.68
- Forward P/E
- 34.48
- Dividend yield
- -
- 52-week range
- $500.61$769.98
- Volume (live)
- -
- Avg. volume (3M)
- 516.11K
IDEXX Laboratories (IDXX) Stock Price & Financial Analysis
IDEXX Laboratories Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $557.94 - $571.75 |
|---|---|
| 52-Week High | $769.98 |
| 52-Week Low | $500.61 |
| Open | $564.23 |
| Volume (last close) | 531.84K |
| Average Volume (3M) | 516.11K |
| Revenue (TTM) | 4.55B |
|---|---|
| Net Income (TTM) | 1.14B |
| Free Cash Flow (TTM) | 1.24B |
| EPS (TTM) | $14.22 |
| Profit Margin | 25.03% |
| Operating Margin | 32.03% |
| Return on Equity (ROE) | 70.67% |
| Debt to Equity | 0.68 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 45.22B |
|---|---|
| Shares Outstanding | 79.31M |
| P/E Ratio (TTM) | 39.68 |
| Forward P/E | 34.48 |
| Price to Sales (P/S) | 9.93 |
| Price to Book (P/B) | 28.04 |
| EV/EBITDA | 28.22 |
| 50-Day MA | $533.88 |
|---|---|
| 200-Day MA | $578.51 |
| 1-Year Change | −11.25% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
IDEXX Laboratories at a Glance
As of the Oct 26, 2026 close, IDEXX Laboratories (IDXX) has a market capitalization of $45.22B. The stock trades at 39.7× trailing earnings, 34.5× forward earnings and 9.9× sales. Over the trailing twelve months it earned $1.14B on revenue of $4.55B (a 25.0% profit margin) and generated $1.24B of free cash flow. Revenue grew 12.8% year over year.
As of its latest reported balance sheet, it holds $196.93M in cash and securities against $1.10B of debt, a net debt position of $899.15M.
IDEXX Laboratories does not currently pay a dividend.
The share price is down 11.2% over the past year. At $570.21 (the Oct 26, 2026 close) it sits within its 52-week range of $500.61 to $769.98, below its 200-day moving average of $578.51.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $710.63, 24.6% above the Oct 26, 2026 close.
Frequently Asked Questions About IDEXX Laboratories
What is the current stock price for IDXX?
As of the Oct 26, 2026 close, IDXX stock trades at $570.21. The 52-week range is $500.61–$769.98, with a day range of $557.94–$571.75.
What is the P/E ratio for IDXX?
As of the Oct 26, 2026 close, IDEXX Laboratories's trailing twelve-month (TTM) P/E ratio is 39.7, meaning investors pay $39.7 for every $1 of annual earnings. The forward P/E is 34.5, reflecting analyst expectations for future earnings. IDEXX Laboratories operates in the Healthcare sector.
Does IDXX pay dividends?
IDEXX Laboratories does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for IDXX?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for IDXX is Buy. The average 12-month price target is $710.63, a 24.6% upside from the Oct 26, 2026 close of $570.21.
What is the market cap of IDXX?
As of the Oct 26, 2026 close, IDEXX Laboratories's market capitalization is $45.22B, classifying it as a large-cap company. IDEXX Laboratories operates in the Healthcare sector within the Diagnostics & Research industry.